Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

NCT04530136 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Confirmed Coronavirus Disease

Interventions

DRUG: Ruconest

Sponsor

Pharming Technologies B.V.